Neurocrine Biosciences, Inc (NBIX) Stock AnalysisNBIXNeurocrine Biosciences, Inc

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Neurocrine Biosciences Inc is a good buy right now due to its current price of $142.44, which is significantly below the average analyst price target of $221, suggesting a potential upside of 55%. Additionally, the forward P/E ratio of 14.12 indicates attractive valuation compared to its growth prospects. However, the main risk is the safety concerns surrounding the VYKAT XR acquisition, which has led to a 25% pullback in stock price since Q2.

13 analysts cover NBIX: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 179.68.